BioCatalystWatch
SNYWorkspace / SNY / OverviewCompany library
Price
Market cap
Next catalystExpected Q4 2026Sarclisa (isatuximab-irfc) · Phase 3 dataCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

PreINDP1P2P3FilingApproved
Upcoming / outlook

M6P receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

PreINDP1P2FilingApproved
Upcoming / outlook

  • Timing and evidence

tolebrutinib

BTK

Approved

PreINDP1P2P3FilingApproved

Approved

PreINDP1P2P3FilingApproved

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

M6P receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

PreINDP1P2FilingApproved
Upcoming / outlook

  • Timing and evidence

PreINDP1P2P3FilingApproved
Upcoming / outlook

tolebrutinib

BTK

Approved

PreINDP1P2P3FilingApproved

Other pipelines

lunsekimig

TSLP × IL-13 × Albumin

PreINDP1P2P3FilingApproved
SP0087

PreINDP1P2P3FilingApproved
Wayrilz (rilzabrutinib)

BTK

Apolipoprotein C-III (apoC-III)

Partner / License out

Approved / commercial

Meningococcal A/C/W/Y antigens

Approved

PreINDP1P2P3FilingApproved

Antithrombin (AT)

Approved

PreINDP1P2P3FilingApproved
Dupixent (dupilumab)

IL-4 × IL-13

Approved

PreINDP1P2P3FilingApproved
Dupixent (dupilumab)

IL-4 × IL-13

Approved

PreINDP1P2P3FilingApproved

History / paused

duvakitug

TL1A

PreINDP1P2P3FilingApproved

IRAK4

PreINDP1P2P3FilingApproved

SSTR

PreINDP1P2P3FilingApproved

Approved

PreINDP1P2P3FilingApproved

IL-6R

PreINDP1P2P3FilingApproved

PD-1

Approved

PreINDP1P2P3FilingApproved
tolebrutinib

BTK

PreINDP1P2P3FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

SNY SEC archive